captopril
These data may explain why, in the CAPP       trial, captopril which has prevented more effectively diabetes occurrence could       not be proved superior to diuretics and/or betablocker in the prevention of       myocardial infarction and specially of strokes for which exist on the contrary a        suspicion of a lower protection.
These data may explain why, in the CAPP       trial,  @SUBJECT$  which has  @PREDICAT$  more effectively  @OBJECT$  occurrence could       not be proved superior to diuretics and/or betablocker in the prevention of       myocardial infarction and specially of strokes for which exist on the contrary a        suspicion of a lower protection.